Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...

The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.

The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.

The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted ...

This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, aggressive state, is a universally recognized sign of poor prognosis across ...

A research team led by scientists at the Butantan Institute in São Paulo, Brazil, has completed the most extensive genetic sequencing of a jararaca viper to date. The focus of the study was the genome ...